Abcam, ab280367, Anti-Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 antibody [EPR24135-98] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24135-98,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab280367 is the carrier-free version of
ab259859
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Nicotinic Acetylcholine Receptor alpha 5 (CHRNA5) also known as the nicotinic receptor plays a mechanical role as part of the heteromeric nicotinic acetylcholine receptor (nAChR) complex. It is a subunit that contributes to the formation of ligand-gated ion channels sensitive to acetylcholine a neurotransmitter. The receptor's mass varies depending on the specific subunit composition but is generally around 55 kDa. CHRNA5 expression occurs mainly in the central nervous system including areas like the brain and spinal cord and it also shows expression in some peripheral tissues.
Biological function summary
The Nicotinic Acetylcholine Receptor alpha 5 modulates neural signaling by affecting the flow of ions through its channel which is activated upon acetylcholine binding. It is part of a complex that includes other nicotinic acetylcholine receptor subunits forming a transmembrane channel. This receptor complex adjusts neurotransmission dynamics and influences synaptic plasticity. It plays roles in cognitive processes and behavioral regulation through its modulation of cholinergic signaling pathways.
Pathways
The Nicotinic Acetylcholine Receptor alpha 5 influences neural signaling through involvement in the cholinergic and dopamine pathways. It interacts with proteins like CHRNA4 and CHRNB2 integral components of these pathways where it modulates synaptic activity and neurotransmission. The receptor's function impacts neurotransmitter release which is critical for processing cognitive and reward-related signals in the brain.
The Nicotinic Acetylcholine Receptor alpha 5 has links to nicotine addiction and schizophrenia. Genetic variations in CHRNA5 are associated with increased risk for nicotine dependence suggesting its role in addiction pathways. Studies implicate it in schizophrenia where its altered expression or function might affect dopaminergic signaling balance. The receptor's association with proteins like CHRNA4 highlights its involvement in disorders through complex interactions in neural transmission.